title: [Primary lymphomas of bones and soft tissues: comparative assessment of treatment results].
abstract: OBJECTIVE
  To evaluate the efficiency of intensive polychemotherapy (PCT) in adult patients having diffuse large B-cell lymphoma (DLBL) of bones and soft tissues with and without poor prognostic factors (PPF).
  
  
  METHODS
  Out of 58 enrolled patients, 51 were diagnosed as having DLBL. Burkitt's lymphoma (BL) was diagnosed in 6 patients. One patient had marginal zone B-cell lymphoma. Thirty-five patients with DLBL (10 patients with PPF and 25 without PPF) and 3 patients with BL were treated with the CHOP/R-CHOP regimen. The NHL-BFM-90 program was used in 3 patients with BL and 16 with DLBL (15 patients with PPF and 1 patient without PPF).
  
  
  RESULTS
  After radiotherapy, the patient with marginal zone B-cell lymphoma achieved a 20-month remission; three BL patients receiving CHOP died. All the BL patients receiving NHL-BFM-90 achieved complete remissions of 48 to 72 months. In 9 patients having DLBL without PPF, who received CHOP, five-year overall and event-free survival rates were 100%; in 22 patients with PPF, these were 50 and 45%, respectively. In the patients with and without PPF, who received CHOP/R-CHOP, the survival rates differed statistically significantly (p = 0.01; logrank test). In the group of 15 patients having DLBL with PPF, who were treated with the NHL-BFM-90 protocol, 14 achieved an average remission of 17 months. In the patients having DLBL with PPF who used NHF-BFM-90, therapeutic efficiency was significantly higher (p = 0.05; Fisher's exact test).
  
  
  CONCLUSIONS
  Differential therapy for primary lymphomas of bones and soft tissues indicated that the NHL-BFM-90 protocol used in the PPF group was significantly more effective than the CHOP regimens.
authors.forename: A K
authors.initials: AK
authors.lastname: Morozova
authors.forename: E E
authors.initials: EE
authors.lastname: Zvonkov
authors.forename: V E
authors.initials: VE
authors.lastname: Mamonov
authors.forename: A M
authors.initials: AM
authors.lastname: Kremenetskaia
authors.forename: S K
authors.initials: SK
authors.lastname: Kravchenko
authors.forename: M A
authors.initials: MA
authors.lastname: Tseĭtlina
authors.forename: D L
authors.initials: DL
authors.lastname: Stroiakovskiĭ
authors.forename: E A
authors.initials: EA
authors.lastname: Bapiakh
authors.forename: A U
authors.initials: AU
authors.lastname: Magomedova
authors.forename: T N
authors.initials: TN
authors.lastname: Obukhova
authors.forename: K D
authors.initials: KD
authors.lastname: Kaplanov
authors.forename: L A
authors.initials: LA
authors.lastname: Pustovoĭt
authors.forename: A I
authors.initials: AI
authors.lastname: Lukina
authors.forename: É G
authors.initials: ÉG
authors.lastname: Gemdzhian
authors.forename: E K
authors.initials: EK
authors.lastname: Egorova
authors.forename: M Iu
authors.initials: MIu
authors.lastname: Pen'kov
authors.forename: A I
authors.initials: AI
authors.lastname: Vorob'ev
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012074:Remission Induction / Q000379:methods; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015996:Survival Rate; D013997:Time Factors; D055815:Young Adult